Teleflex Inc., a leading medical technology company, has amended its Third Amended and Restated Credit Agreement dated November 4, 2022. The amendment, finalized on June 24, 2025, introduces additional delayed draw term loan commitments amounting to $200 million. This enhances the company's Delayed Draw Term Loan Facility to a total of $700 million, supporting its planned acquisition of the Vascular Intervention business segment from MS Holding II SE. The terms of the facility remain largely unchanged, ensuring continued financial flexibility for Teleflex's strategic growth initiatives.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.